



March 29, 2025

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), this is to inform that the Company has received Cautionary Letter by email from the stock exchanges regarding the intimation of Schedule of Investors/ Analysts' Meet/ Call.

As mentioned in the Cautionary letters, the copy of the same are enclosed herewith for dissemination. Further, the content of the said letters is noted and the Company shall adhere to the compliance stated therein.

The relevant information in the format prescribed by SEBI vide its circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is as under:

Name of the authority	BSE Limited and National Stock Exchange of India Limited.
Nature and details of the action(s) taken, initiated or order(s) passed	Cautionary letters issued by BSE Limited and National Stock Exchange of India Limited vide email.

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com



GOOD PEOPLE
for **GOOD HEALTH**

Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	March 28, 2025
Details of the violation(s)/contravention(s) committed or alleged to be committed	Delay in disclosure of intimation of participation in Investors/ Analysts' Meet/ Call to the stock exchanges in accordance with the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on financial, operation or other activities of the Company due to this cautionary letter.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary

Registered Office:


J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com

Ruchi Shah

From:
Sent:
To:
Subject:



----- Forwarded message -----

From: Query lodr <query.lodr@bseindia.com>
Date: 28 Mar 2025 16:22
Subject: Cautionary Letter
To: Investo Relations <investorelations@jbpharma.com>
Cc:

LIST/COMP/JP/1760/2024-25
March 28, 2025

Date:

To,
Company Secretary /Compliance Officer
JB Chemicals & Pharmaceuticals Ltd (506943)

Sub: Cautionary letter

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on September 06, 2024, regarding the intimation of Schedule of Investors/ Analysts' Meet/ Call to be held on September 10, 2024

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet/call).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.


The Company is required to disseminate a copy of this Cautionary Letter on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary Letter and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

Yours faithfully,

Listing Compliance Monitoring Team
BSE Limited
P J Towers, Dalal Street,
Mumbai - 400001, India
www.bseindia.com
Tel: 022 2272 8561 / 8475

Ruchi Shah

From:
Sent:
To:
Subject:



From: neaps@nse.co.in <neaps@nse.co.in>
Sent: Friday, March 28, 2025 5:21:56 PM
To: Secretarial
Subject: JBCHEPHARM - Cautionary Email

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on September 06, 2024 regarding the intimation of Schedule of Investors/ Analysts Meet/call to be held on September 10, 2024.

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed.

Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at takeover@nse.co.in.